z-logo
open-access-imgOpen Access
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Author(s) -
JeanClaude Tardif,
Simon Kouz,
David D. Waters,
Olivier F. Bertrand,
Rafael Díaz,
Aldo P. Maggioni,
Fausto J. Pinto,
Réda Ibrahim,
Habib Gamra,
Ghassan S. Kiwan,
Colin Berry,
José LópezSendón,
Petr Ošťádal,
Wolfgang Köenig,
Denis Angoulvant,
Jean C. Grégoire,
Marc-André Lavoie,
MariePierre Dubé,
David Rhainds,
Mylène Provencher,
Lucie Blondeau,
Andreas Orfanos,
Philippe L. L’Allier,
MarieClaude Guertin,
François Roubille
Publication year - 2019
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1912388
Subject(s) - colchicine , gout , medicine , pericarditis , myocardial infarction , inflammation , pharmacology , cardiology
Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom